Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Company raises the annual revenue guidance from mid-teens to high teens
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
Syngene's collaboration with Zoetis started in 2011
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Subscribe To Our Newsletter & Stay Updated
